LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Aandelen Lijst・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Gesloten

SectorGezondheidszorg

54.89 0.96

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

54.31

Max

55.05

Belangrijke statistieken
By Trading Economics
Inkomsten	1.6B 2.7B
Verkoop	-1B 11B
K/W Sectorgemiddelde	15.392 49.888
EPS	1.31
Dividendrendement	4.37
Winstmarge	23.309
Werknemers	32,500
EBITDA	1.5B 3.7B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+16.25% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	4.37% 2.38%
Volgende Winsten	30 jul 2026
Volgende dividenddatum	31 jul 2026
Volgende Ex Dividend datum	2 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-5.8B 112B
Vorige openingsprijs	53.93
Vorige sluitingsprijs	54.89

Bristol-Myers Squibb Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 jun 2026, 13:08 UTC

Winsten

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

12 mei 2026, 06:42 UTC

Belangrijke Marktbewegers

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30 apr 2026, 11:14 UTC

Winsten

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

29 mei 2026, 08:15 UTC

Marktinformatie

Winsten

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

5 mei 2026, 18:12 UTC

Winsten

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mei 2026, 13:54 UTC

Winsten

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 apr 2026, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 apr 2026, 14:13 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 12:57 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 11:19 UTC

Winsten

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 apr 2026, 10:34 UTC

Winsten

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 apr 2026, 21:23 UTC

Winsten

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Peer Vergelijking

Prijswijziging

Bristol-Myers Squibb Co. Prognose

Koersdoel

By TipRanks

16.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 63.31 USD 16.25%

Hoogste 75 USD

Laagste 40 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bristol-Myers Squibb Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan Bristol-Myers Squibb Co. - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.